Skip to main content

Table 1 Demographic and clinical characteristics of the patients at baseline

From: Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study

 

Patients who entered the CBT but did not complete

Patients who completed the CBT but not the 3-month FU assessments

Patients who completed the the 3-month but not the 12-month FU assessments

Patients who provided both FU assessments

P value

Number of subjects

9

4

4

40

 

Female, No. (%)

3 (33.3)

2 (50.0)

2 (50.0)

23 (57.5)

0.63

Age, years

     

   Mean ± SD

27.4 ± 8.8

34.2 ± 9.3

34.2 ± 9.3

34.2 ± 8.9

0.12

   Range

18-47

18-52

18-52

18-52

 

Onset of SAD, years

     

   Mean ± SD

17.1 ± 4.2

19.4 ± 7.8

19.4 ± 7.8

19.6 ± 7.8

0.12

   Range

12-23

5-42

5-42

5-42

 

Living situation, No (%)

    

0.03*

   With spouse/significant-other

0 (0.0)

1 (25.0)

2 (50.0)

20 (50.0)

 

   With parents

5 (55.6)

3 (75.0)

2 (50.0)

16 (40.0)

 

   Alone

4 (44.4)

0 (0.0)

0 (0.0)

4 (10.0)

 

Employment

    

0.61

   Full-time employment

2 (22.2)

1 (25.0)

1 (25.0)

10 (25.0)

 

   Full-time student

2 (22.2)

0 (0.0)

0 (0.0)

2 (5.0)

 

   Part-time/homemaker/retired

3 (33.3)

2 (50.0)

3 (75.0)

23 (55.0)

 

   Unemployed

2 (22.2)

1 (25.0)

0 (0.0)

6 (15.0)

 

Education, No. (%)

    

0.61

   University

2 (22.2)

1 (25.0)

1 (25.0)

15 (37.5)

 

   College

1 (11.1)

3 (75.0)

1 (25.0)

10 (25.0)

 

   High school or less

6 (66.6)

0 (0.0)

2 (50.0)

15 (37.5)

 

Social phobia, No. (%) generalized

8 (88.8)

4 (100.0)

3 (75.0)

34 (85.0)

0.72

Comorbidity, No. (%)

     

   Mood disorders

2 (22.2)

4 (100.0)

2 (50.0)

14 (35.0)

0.05

   Anxiety disorders

1 (11.1)

1 (25.0)

0 (0.0)

4 (10.0)

0.71

Medication, No. (%)

     

   Benzodiazepine

4 (44.4)

0 (0.0)

1 (25.0)

11 (27.5)

0.20

   Antidepressant

7 (77.8)

2 (50.0)

2 (50.0)

20 (50.0)

0.50

SF-36

     

   Physical functioning

85.6 ± 14.7

91.3 ± 11.8

82.5 ± 22.2

88.6 ± 14.3

0.79

   Role-physical

75.0 ± 43.3

62.5 ± 43.3

56.3 ± 51.5

68.6 ± 36.6

0.87

   Bodily pain

90.3 ± 19.4

64.3 ± 29.4

66.5 ± 32.5

65.8 ± 25.3

0.08

   General health perception

47.2 ± 22.4

49.8 ± 26.3

44.3 ± 26.3

45.1 ± 22.1

0.98

   Vitality

42.2 ± 23.6

45.0 ± 5.8

20.0 ± 18.3

39.6 ± 21.1

0.28

   Social functioning

45.8 ± 23.4

56.3 ± 21.7

65.6 ± 38.7

58.7 ± 30.2

0.63

   Role-emotional

51.9 ± 44.4

50.0 ± 43.0

41.7 ± 50.0

57.3 ± 40.4

0.89

   Mental health

44.9 ± 14.9

48.0 ± 3.3

36.0 ± 15.0

47.9 ± 20.5

0.67

SPS (total)

44.0 ± 13.7

47.3 ± 28.0

34.0 ± 6.2

33.7 ± 12.5

0.08

SIAS (total)

55.3 ± 9.8

64.5 ± 26.4

51.3 ± 11.2

51.0 ± 13.3

0.29

SCL-90-R depression

1.67 ± 0.96

1.52 ± 0.75

1.35 ± 0.89

1.50 ± 0.87

0.93

  1. P-values were calculated using one-way ANOVA for continuous variables and using χ2 statistic for categorical variables.
  2. Appendices: FU, follow-up; SAD, social anxiety disorder; SCL-90-R, Symptom Checklist-90-Revised; SF-36, Short Form 36; SIAS, Social Interaction Anxiety; SPS, Social Phobia Scale
  3. (* P < 0.05, ** P < 0.005)
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us